AEON Biopharma will host investor meetings at Lake Street Capital's conference in NYC on September 10, 2026.
Quiver AI Summary
AEON Biopharma, Inc. announced that its management will conduct in-person one-on-one investor meetings at Lake Street Capital Markets' 10th Annual Best Ideas Growth Conference in New York City on September 10, 2026. The company is focused on advancing its product ABP-450 as a biosimilar to BOTOX® for therapeutic use, aiming for full-label market entry in the U.S., which is a significant market opportunity valued over $3 billion annually. ABP-450, manufactured by Daewoong Pharmaceutical, shares the same botulinum toxin complex approved for cosmetic use as Jeuveau® by Evolus, Inc., and AEON holds exclusive rights for its therapeutic development and distribution in various regions, including the U.S. and Europe. Further information about the conference and investor inquiries can be directed to Lake Street representatives.
Potential Positives
- AEON Biopharma is actively pursuing full-label U.S. market entry for ABP-450, a biosimilar to BOTOX®, which presents a significant opportunity in a market worth over $3.0 billion annually.
- The company will engage directly with investors at an established conference, providing a platform for potential networking and increased visibility in the financial community.
- AEON holds exclusive development and distribution rights for ABP-450 in large markets, including the U.S., Canada, and the EU, indicating a strong positioning for market access and potential revenue generation.
Potential Negatives
- Announcement lacks critical information about ABP-450's current development status and timeline for market entry, which could raise concerns for investors regarding the viability of the product.
- The release does not address potential competition or challenges AEON might face in the U.S. therapeutic neurotoxin market, which could impair investor confidence.
- Failure to highlight any recent achievements or milestones may suggest a lack of progress or urgency in the company's development efforts.
FAQ
What is AEON Biopharma's main focus?
AEON Biopharma focuses on advancing ABP-450 as a biosimilar to BOTOX® for therapeutic uses in the U.S. market.
When will AEON participate in the BIG10 Conference?
AEON will host in-person investor meetings at the BIG10 Conference on Thursday, September 10th, 2026, in New York City.
How can I schedule a meeting with AEON management?
To schedule a one-on-one meeting, contact your Lake Street Representative for assistance and an invitation.
What is the potential market size for AEON's biosimilar?
The U.S. therapeutic neurotoxin market exceeds $3.0 billion annually, presenting a significant opportunity for AEON's biosimilar.
Who manufactures AEON's ABP-450 product?
ABP-450 is manufactured by Daewoong Pharmaceutical in an FDA-authorized facility for third-party botulinum toxin products.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$AEON Insider Trading Activity
$AEON insiders have traded $AEON stock on the open market 1 times in the past 6 months. Of those trades, 1 have been purchases and 0 have been sales.
Here’s a breakdown of recent trading of $AEON stock by insiders over the last 6 months:
- TIMOTHY P LYNCH purchased 1,150,000 shares for an estimated $243,455
To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API insider transaction endpoint.
$AEON Hedge Fund Activity
We have seen 9 institutional investors add shares of $AEON stock to their portfolio, and 8 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- DAUNTLESS INVESTMENT GROUP, LLC added 9,962,379 shares (+394.1%) to their portfolio in Q2 2026, for an estimated $7,165,939
- XTX TOPCO LTD removed 20,424 shares (-100.0%) from their portfolio in Q2 2026, for an estimated $14,690
- STONEX GROUP INC. added 18,953 shares (+inf%) to their portfolio in Q2 2026, for an estimated $13,632
- JANE STREET GROUP, LLC removed 16,376 shares (-100.0%) from their portfolio in Q2 2026, for an estimated $11,779
- LAIRD NORTON WETHERBY TRUST COMPANY, LLC removed 15,000 shares (-100.0%) from their portfolio in Q1 2026, for an estimated $14,775
- TWO SIGMA SECURITIES, LLC removed 13,180 shares (-100.0%) from their portfolio in Q1 2026, for an estimated $12,982
- CITADEL ADVISORS LLC removed 11,642 shares (-100.0%) from their portfolio in Q1 2026, for an estimated $11,467
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.
Full Release
ALISO VIEJO, Calif., Aug. 31, 2026 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc. (“AEON” or the “Company”) (NYSE American: AEON), a biopharmaceutical company advancing ABP-450 as a biosimilar to BOTOX ® (onabotulinumtoxinA) for therapeutic use to achieve full-label U.S. market entry, announced today that AEON management will host in-person 1x1 investor meetings at Lake Street Capital Markets’ 10 th Annual Best Ideas Growth (BIG10) Conference being held in New York City on Thursday, September 10 th , 2026.
To receive additional information about the Conference, request an invitation or to schedule a one-on-one meeting, please contact your Lake Street Representative.
About AEON Biopharma
AEON Biopharma is a biopharmaceutical company pursuing full-label access to the U.S. therapeutic neurotoxin market via biosimilarity to BOTOX ® . The U.S. therapeutic neurotoxin market exceeds $3.0 billion annually, representing a major opportunity for biosimilar entry. ABP-450 is the same botulinum toxin complex currently approved and marketed for cosmetic indications by Evolus, Inc. under the name Jeuveau ® . ABP-450 is manufactured by Daewoong Pharmaceutical in a facility that has been authorized by the U.S. Food and Drug Administration, Health Canada, and European Medicines Agency for the manufacture of third-party botulinum toxin products. AEON has exclusive development and distribution rights for therapeutic indications of ABP-450 in the United States, Canada, the European Union, the United Kingdom, and certain other international territories. To learn more about AEON, visit www.aeonbiopharma.com .
Contacts
Investor Contact:
Hershel Berry
Blueprint Life Science Group
[email protected]
Source: AEON
